peyronie's research
Posted: Fri Dec 12, 2014 1:14 pm
Novel Peyronie's Disease Treatment Shows Efficacy
Share this article:
facebook
twitter
linkedin
google
Is Provenge, which demonstrated only a modest survival benefit, worth the price?
Penile traction therapy reduced curvature and significantly improved function and hardness.
Penile traction therapy (PTT) is an effective treatment for the acute phase of Peyronie's disease (PD), Spanish researchers reported in The Journal of Sexual Medicine (2014;11:506-515).
Juan Martínez-Salamanca, MD, PhD, of the Department of Urology at the Autonomous University of Madrid and colleagues studied 55 patients who underwent PTT, a novel penile extender device therapy, for 6 months for acute phase (AP) of Peyronie's. These patients were compared with 41 patients in the acute phase of Peyronie's disease who received no active treatment.
From baseline, mean curvature in patients treated with PTT had decreased from 33° to 15° at 6 months and 13° at 9 months, with a mean decrease of 20°. Erectile function and hardness improved significantly, and the proportion of patients unable to achieve penetration decreased from 62% to 20%.
The need for surgery was reduced in 40% of patients who would otherwise have been eligible, and the complexity of surgical procedures was further simplified in 1 out of 3 patients. PTT was associated with the removal of sonographic plaques in 48% of patients treated.
The non-active treatment group had a significant increase in penile deformity, where function and hardness worsened and stretched flaccid penile length had decreased.
“PTT seems an effective treatment for the AP of PD in terms of pain reduction, penile curvature decrease, and improvement in sexual function,” the authors concluded.
From the May 2014 Issue of Renal And Urology News »
Share this article:
Is Provenge, which demonstrated only a modest survival benefit, worth the price?
Penile traction therapy reduced curvature and significantly improved function and hardness.
Penile traction therapy (PTT) is an effective treatment for the acute phase of Peyronie's disease (PD), Spanish researchers reported in The Journal of Sexual Medicine (2014;11:506-515).
Juan Martínez-Salamanca, MD, PhD, of the Department of Urology at the Autonomous University of Madrid and colleagues studied 55 patients who underwent PTT, a novel penile extender device therapy, for 6 months for acute phase (AP) of Peyronie's. These patients were compared with 41 patients in the acute phase of Peyronie's disease who received no active treatment.
From baseline, mean curvature in patients treated with PTT had decreased from 33° to 15° at 6 months and 13° at 9 months, with a mean decrease of 20°. Erectile function and hardness improved significantly, and the proportion of patients unable to achieve penetration decreased from 62% to 20%.
The need for surgery was reduced in 40% of patients who would otherwise have been eligible, and the complexity of surgical procedures was further simplified in 1 out of 3 patients. PTT was associated with the removal of sonographic plaques in 48% of patients treated.
The non-active treatment group had a significant increase in penile deformity, where function and hardness worsened and stretched flaccid penile length had decreased.
“PTT seems an effective treatment for the AP of PD in terms of pain reduction, penile curvature decrease, and improvement in sexual function,” the authors concluded.
From the May 2014 Issue of Renal And Urology News »